Harvard Medical School researchers have found that statin use significantly reduces the risk of hepatocellular carcinoma (HCC ...

The FDA has issued a complete response letter for rivoceranib plus camrelizumab as a first-line treatment for unresectable ...

For patients with chronic liver disease, statin use is associated with a reduced risk for hepatocellular carcinoma (HCC) and ...

Hepatocellular carcinoma (HCC), the third leading cause of cancer-related deaths worldwide, remains one of the most ...

The analysis included 16,501 participants: 3610 statin users and 12,891 nonusers. HealthDay News — For patients with chronic liver disease, statin use is associated with a reduced risk for ...

Hepatocellular carcinoma (HCC), the most common type of primary liver cancer, accounts for about 75–85% of all liver cancer ...

Direct-acting antivirals (DAAs) have dramatically changed the landscape of chronic hepatitis C virus (HCV) treatment and ...

Residual cancer can remain undetected despite clear scans, potentially leading to worse outcomes and higher risks of ...

Despite appearing successful on scans, radiotherapy may leave behind undetected microscopic cancer cells, posing a greater ...

While radiotherapy is a highly effective cancer treatment -- useful for about 60 per cent of all cancers -- it may lead to ...

Radiotherapy may leave behind microscopic cancer even when scan images suggest the tumour is gone, and this“residual diseas ...